DE3581856D1 - Steroidester enthaltende liposome. - Google Patents

Steroidester enthaltende liposome.

Info

Publication number
DE3581856D1
DE3581856D1 DE8585850222T DE3581856T DE3581856D1 DE 3581856 D1 DE3581856 D1 DE 3581856D1 DE 8585850222 T DE8585850222 T DE 8585850222T DE 3581856 T DE3581856 T DE 3581856T DE 3581856 D1 DE3581856 D1 DE 3581856D1
Authority
DE
Germany
Prior art keywords
sub
steroides
sup
compounds
inflammatory conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585850222T
Other languages
English (en)
Inventor
Bengt Ingemar Axelsson
Ralph Lennart Brattsand
Carl Magnus Olof Dahlbaeck
Leif Arne Kaellstroem
Jan William Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Draco AB
Original Assignee
Draco AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Draco AB filed Critical Draco AB
Application granted granted Critical
Publication of DE3581856D1 publication Critical patent/DE3581856D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
DE8585850222T 1984-07-30 1985-06-28 Steroidester enthaltende liposome. Expired - Lifetime DE3581856D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8403905A SE8403905D0 (sv) 1984-07-30 1984-07-30 Liposomes and steroid esters

Publications (1)

Publication Number Publication Date
DE3581856D1 true DE3581856D1 (de) 1991-04-04

Family

ID=20356623

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585850222T Expired - Lifetime DE3581856D1 (de) 1984-07-30 1985-06-28 Steroidester enthaltende liposome.

Country Status (29)

Country Link
US (1) US4693999A (de)
EP (1) EP0170642B1 (de)
JP (1) JPS6143110A (de)
KR (1) KR930000045B1 (de)
AT (1) ATE60990T1 (de)
AU (1) AU582173B2 (de)
CA (1) CA1250830A (de)
CS (1) CS254342B2 (de)
CY (1) CY1731A (de)
DD (2) DD248055A5 (de)
DE (1) DE3581856D1 (de)
DK (1) DK164509C (de)
EG (1) EG17462A (de)
ES (2) ES8704969A1 (de)
FI (1) FI84914C (de)
HK (1) HK78293A (de)
HU (1) HU196827B (de)
IE (1) IE58074B1 (de)
IS (1) IS1515B (de)
NO (1) NO168042C (de)
NZ (1) NZ212861A (de)
PH (1) PH21644A (de)
PL (1) PL145673B1 (de)
PT (1) PT80884B (de)
SE (1) SE8403905D0 (de)
SG (1) SG69093G (de)
SU (1) SU1493111A3 (de)
YU (1) YU45735B (de)
ZA (1) ZA855032B (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
SE8501693D0 (sv) * 1985-04-04 1985-04-04 Draco Ab Novel 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters
SE8506015D0 (sv) * 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8601457D0 (sv) * 1986-04-01 1986-04-01 Draco Ab Compositions of liposomes and b?712-receptor active substances for inhalation
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
FR2619505B1 (fr) * 1987-08-20 1990-08-31 Dior Christian Parfums Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant de la pregnenolone ou un ester de pregnenolone, et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite regeneratrice ou revitalisante, l'incorporant
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
EP0397774A1 (de) * 1988-02-04 1990-11-22 Board Of Regents, The University Of Texas System Formulierung und anwendung von retinoiden für behandlung von krebs und anderen krankheiten
US5043165A (en) * 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US6001335A (en) * 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US20020150539A1 (en) 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
FR2675146A1 (fr) * 1991-04-10 1992-10-16 Roussel Uclaf Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
NZ259596A (en) * 1993-01-08 1997-04-24 Astra Ab Sugar-substituted glucocorticosteroid and use in medicaments specific to the colon or ileum
WO1994028876A1 (en) * 1993-06-07 1994-12-22 Advanced Therapies, Inc. Liposome powders
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5635206A (en) * 1994-01-20 1997-06-03 Hoffmann-La Roche Inc. Process for liposomes or proliposomes
CH689139A5 (de) * 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5997898A (en) * 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
JP2001507207A (ja) 1996-05-01 2001-06-05 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 化合物を細胞に送達する方法
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
US5958378A (en) * 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
CA2263568C (en) * 1996-09-11 2008-12-02 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a contrast agent and a renal vasodilator
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
AU6974798A (en) * 1997-05-06 1998-11-27 Imarx Pharmaceutical Corp. Novel prodrugs comprising fluorinated amphiphiles
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
CA2670236C (en) 1999-09-30 2012-06-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
JP2003520210A (ja) * 2000-01-05 2003-07-02 イマレックス セラピューティクス， インコーポレイテッド 低い水溶性を有する薬物の送達のための薬学的処方物
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
DE10116197A1 (de) * 2001-03-30 2002-10-17 Bernina Biosystems Gmbh Neue Methylprednisolonderivate mit therapeutischer Wirkung
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
AU2003217535A1 (en) 2002-02-20 2003-09-09 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids
EP1490027A4 (de) * 2002-03-05 2010-11-10 Transave Inc Verfahren zum einfangen eines wirkstoffs in einem liposom oder lipidkomplex
US20040235811A1 (en) * 2002-10-08 2004-11-25 Sepracor Inc. Fatty acid modified forms of glucocorticoids
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
CN1747738B (zh) * 2002-10-29 2010-11-24 川塞夫有限公司 缓释抗感染剂
AU2003257154A1 (en) * 2003-08-05 2005-03-07 Sepracor Inc. AMINO ACID AND PEPTIDE-MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH ss2 ADRENERGIC AGONISTS
DK1962805T3 (en) 2005-12-08 2016-09-26 Insmed Inc Lipid-based compositions of the anti-infective agents for the treatment of lung infections
NO331891B1 (no) * 2007-03-20 2012-04-30 Clavis Pharma Asa Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
LT2852391T (lt) 2012-05-21 2022-03-10 Insmed Incorporated Plaučių infekcijų gydymo būdai
AU2013352259B2 (en) 2012-11-29 2018-06-14 Insmed Incorporated Stabilized vancomycin formulations
ES2926985T3 (es) 2014-05-15 2022-10-31 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
KR101961484B1 (ko) * 2016-01-08 2019-03-22 최규선 생콩 탈피장치
EP3773505A4 (de) 2018-03-30 2021-12-22 Insmed Incorporated Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE378109B (de) * 1972-05-19 1975-08-18 Bofors Ab
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
CH621479A5 (de) * 1977-08-05 1981-02-13 Battelle Memorial Institute
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
JPS609726B2 (ja) * 1980-05-15 1985-03-12 株式会社 ミドリ十字 ステロイド製剤
HU182775B (en) * 1981-10-15 1984-03-28 Richter Gedeon Vegyeszet Process for preparing new 3-chloro-pregnane derivatives
DE3228629A1 (de) * 1982-07-31 1984-02-02 Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung
GB2135647A (en) * 1983-02-15 1984-09-05 Squibb & Sons Inc Method of preparing liposomes and products produced thereby

Also Published As

Publication number Publication date
NO168042B (no) 1991-09-30
CA1250830A (en) 1989-03-07
HUT39460A (en) 1986-09-29
FI852932L (fi) 1986-01-31
DD236535A5 (de) 1986-06-11
PT80884B (pt) 1987-11-30
IS3026A7 (is) 1986-01-31
US4693999A (en) 1987-09-15
IE851892L (en) 1986-01-30
NZ212861A (en) 1989-01-27
IE58074B1 (en) 1993-06-30
FI84914C (fi) 1992-02-10
ZA855032B (en) 1986-03-26
SE8403905D0 (sv) 1984-07-30
DK336385D0 (da) 1985-07-24
HU196827B (en) 1989-01-30
IS1515B (is) 1992-11-04
DD248055A5 (de) 1987-07-29
SU1493111A3 (ru) 1989-07-07
ES557143A0 (es) 1987-05-16
PL254681A1 (en) 1986-11-18
JPH0459297B2 (de) 1992-09-21
ATE60990T1 (de) 1991-03-15
NO852672L (no) 1986-01-31
PL145673B1 (en) 1988-10-31
PT80884A (en) 1985-08-01
NO168042C (no) 1992-01-08
AU4530785A (en) 1986-02-06
CS254342B2 (en) 1988-01-15
EP0170642B1 (de) 1991-02-27
ES8704969A1 (es) 1987-04-16
AU582173B2 (en) 1989-03-16
EP0170642A3 (en) 1986-10-29
DK164509C (da) 1992-11-23
EG17462A (en) 1991-03-30
HK78293A (en) 1993-08-13
KR930000045B1 (ko) 1993-01-06
DK164509B (da) 1992-07-06
PH21644A (en) 1988-01-13
ES545651A0 (es) 1987-04-16
EP0170642A2 (de) 1986-02-05
CY1731A (en) 1994-05-06
KR860000863A (ko) 1986-02-20
JPS6143110A (ja) 1986-03-01
FI852932A0 (fi) 1985-07-29
DK336385A (da) 1986-01-31
YU123885A (en) 1988-02-29
SG69093G (en) 1993-08-06
YU45735B (sh) 1992-07-20
FI84914B (fi) 1991-10-31
ES8705895A1 (es) 1987-05-16

Similar Documents

Publication Publication Date Title
DE3581856D1 (de) Steroidester enthaltende liposome.
KR850002740A (ko) 페닐에탄올아민 유도체의 제조방법
MY101483A (en) Novel compounds and compositions useful for producing analgesia
EP0311068A3 (en) Polyamine derivatives as antineoplastic agents
DE3175939D1 (en) Use of gamma-piperidino-butyrophenones for the preparation of medicaments for treating diarrhoea
ES2058315T3 (es) Compuestos eficaces contra insuficiencia cerebral.
TH3073EX (th) ไลโพโซมที่มีสเทอรอยด์เอสเทอร์
MY108455A (en) Therapeutic benzazapine compounds.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition